Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Bor-Sheng Ko

24PUBLICATIONS
58CO-AUTHORS
Haematological tumoursTransplantation immunologyCardiovascular medicine and haematology not elsewhere classifiedRespiratory diseasesGene and molecular therapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (24)

Sort by Publication Date:
|Mar 17, 2026
Tailored approaches in mantle cell lymphoma: refining treatment paradigms with an expert panel opinion.

Won Seog Kim, Mubarak Al Mansour, Chan Cheah

|Mar 13, 2026
Prognostic implications of genetic and transcriptomic abnormalities in MDS according to IPSS-R, IPSS-M, and the International Consensus Classification.

Wan-Hsuan Lee, Hsin-An Hou, Chien-Chin Lin

|Jan 06, 2026
Prognostic impact of co-occurring FLT3 mutations across molecular subgroups in intensively treated acute myeloid leukemia: insights from real-world genomic data.

Yu-Sung Chang, Feng-Ming Tien, Yu-Wen Wang

|Dec 18, 2025
Impact of early failure of induction on transplant outcomes in Hodgkin lymphoma.

Yu-Sung Chang, Wan-Chen Hsieh, Hsueh-Mei Chang

|Dec 05, 2025
Letermovir Prophylaxis for CMV DNAemia/Disease after HLA-Mismatched HSCT: A Retrospective Real-World Analysis with Overlap Propensity Score Weighting.

Yi-Che Huang, Shu-Wen Lin, Xavier Cheng-Hong Tsai

|Sep 10, 2025
Taiwan consensus on pulmonary chronic graft-versus-host disease: A joint statement from the Taiwan Society of Blood and Marrow Transplantation (TBMT) and Taiwan Society of Pulmonary and Critical Care Medicine (TSPCCM).

Xavier Cheng-Hong Tsai, Zong-Han Yao, Shu-Wei Chou

Pageof 4

Frequent Collaborators

6 joint publications

Xavier Cheng-Hong Tsai

6 joint publications

Feng-Ming Tien

6 joint publications

Fei-Yuan Hsiao

5 joint publications

Hwei-Fang Tien

5 joint publications

Wen-Chien Chou

4 joint publications

Chien-Chin Lin

4 joint publications

Yu-Sung Chang

4 joint publications

Hsin-An Hou

4 joint publications

Chi-Yuan Yao

4 joint publications

Huai-Hsuan Huang

Frequent Collaborators

6 joint publications

Xavier Cheng-Hong Tsai

6 joint publications

Feng-Ming Tien

6 joint publications

Fei-Yuan Hsiao

5 joint publications

Hwei-Fang Tien

Top Related Videos

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on : Sep 12, 2025

976
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on : Oct 03, 2018

10.2K
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on : Oct 17, 2025

832
See more related videos

Top Related Videos

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma
08:31

Bioprinting of Hydrogel Tumor Slices as a 3D Model for Mantle Cell Lymphoma

Published on : Sep 12, 2025

976
Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on : Oct 03, 2018

10.2K
Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors
04:36

Comet Assay to Quantify DNA Damage in FLT3 Mutant-expressing 32D Cells after Exposure to Type I and Type II FLT3 Inhibitors

Published on : Oct 17, 2025

832
See more related videos